nach oben

Pediatric Nephrology

Erschienen in:

14.03.2023 | Original Article

Primary hyperoxaluria type 1 in children: clinical and laboratory manifestations and outcome

verfasst von: Hala Wannous

Erschienen in: Pediatric Nephrology | Ausgabe 8/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Primary hyperoxaluria (PH) results from genetic mutations in different genes of glyoxylate metabolism, which cause significant increases in production of oxalate by the liver. This study aimed to report clinical and laboratory manifestations and outcome of PH type 1 in children in our center.

Methods

A single-center observational cohort study was conducted at Children’s University Hospital in Damascus, and included all patients admitted from 2018 to 2020, with a diagnosis of hyperoxaluria (urinary oxalate excretion > 45 mg/1.73 m²/day, or > 0.5 mmol/1.73 m²/day). PH type 1 (PH1) diagnosis was established by identification of biallelic pathogenic variants (compound heterozygous or homozygous mutations) in AGXT gene on molecular genetic testing.

Results

The study included 100 patients with hyperoxaluria, with slight male dominance (57%), and median age 1.75 years (range, 1 month–14 years). Initial complaint was urolithiasis or nephrocalcinosis in 47%, kidney failure manifestations in 29%, and recurrent urinary tract infection in 24%. AGXT mutations were detected in 40 patients, and 72.5% of PH1 patients had kidney failure at presentation. Neither gender, age nor urinary oxalate excretion in 24 h had statistical significance in distinguishing PH1 from other forms of hyperoxaluria (P-Value > 0.05). Parental consanguinity, family history of kidney stones, bilateral nephrocalcinosis, presence of oxalate crystals in random urine sample, kidney failure and mortality were statistically significantly higher in PH1 (P-values < 0.05). Mortality was 32.5% among PH1 patients, with 4 PH1 patients (10%) on hemodialysis awaiting combined liver–kidney transplantation.

Conclusion

PH1 is still a grave disease with wide variety of clinical presentations which frequent results in delays in diagnosis, thus kidney failure is still a common presentation. In Syria, we face many challenges in diagnosis of PH, especially PH2 and PH3, and in management, with hopes that diagnosis tools and modern therapies will become available in our country.

Nur mit Berechtigung zugänglich

Alon US, Srivastava T (2017) Urolithiasis in children. In: Kher KK, Schnaper HW, Greenbaum LA (eds) Clinical Pediatric Nephrology, 3rd edn. Boca Raton, pp 1014–1015

Demoulin N, Aydin S, Gillion V, Morelle J, Jadoul M (2022) Pathophysiology and management of hyperoxaluria and oxalate nephropathy: a review. Am J Kidney Dis 79:717–727. https://doi.org/10.1053/j.ajkd.2021.07.018CrossRefPubMed

Danpure CJ (2006) Primary hyperoxaluria type 1: AGT mistargeting highlights the fundamental differences between the peroxisomal and mitochondrial protein import pathways. Biochim Biophys Acta 1763:1776–1784CrossRefPubMed

Harambat J, Fargue S, Bacchetta J, Acquaviva C, Cochat P (2011) Primary hyperoxaluria. Int J Nephrol 2011:864580. https://doi.org/10.4061/2011/864580CrossRef

Milliner DS, Harris PC, Sas DJ, Cogal AG, Lieske JC (2002) Primary Hyperoxaluria Type 1. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A (eds). GeneReviews® [Internet]. University of Washington, Seattle, Seattle, 1993–2022

Weigert A, Martin-Higueras C, Hoppe B (2018) Novel therapeutic approaches in primary hyperoxaluria. Expert Opin Emerg Drugs 23:349–357. https://doi.org/10.1080/14728214.2018.1552940CrossRefPubMed

Garrelfs SF, Rumsby G, Peters-Sengers H, Erger F, Groothoff JW, Beck BB, Oosterveld MJS, Pelle A, Neuhaus T, Adams B, Cochat P, Salido E, Lipkin GW, Hoppe B, Hulton SA, OxalEurope Consortium (2019) Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up. Kidney Int 96:1389–1399. https://doi.org/10.1016/j.kint.2019.08.018CrossRefPubMed

Martin-Higueras C, Garrelfs SF, Groothoff JW, Jacob DE, Moochhala SH, Bacchetta J, Acquaviva C, Zaniew M, Sikora P, Beck BB, Hoppe B (2021) A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3. Kidney Int 100:621–635. https://doi.org/10.1016/j.kint.2021.03.031CrossRefPubMed

Hoppe B (2012) An update on primary hyperoxaluria. Nat Rev Nephrol 8:467–475. https://doi.org/10.1038/nrneph.2012.113CrossRefPubMed

10.

Hoppe B, Martin-Higueras C (2022) Improving Treatment Options for Primary Hyperoxaluria. Drugs 82:1077–1094. https://doi.org/10.1007/s40265-022-01735-xCrossRefPubMedPubMedCentral

11.

Cochat P, Rumsby G (2013) Primary hyperoxaluria. N Engl J Med 369:649–658. https://doi.org/10.1056/NEJMra1301564CrossRefPubMed

12.

Beck BB, Hoyer-Kuhn H, Göbel H, Habbig S, Hoppe B (2013) Hyperoxaluria and systemic oxalosis: an update on current therapy and future directions. Expert Opin Investig Drugs 22:117–129. https://doi.org/10.1517/13543784.2013.741587CrossRefPubMed

13.

Devresse A, Cochat P, Godefroid N, Kanaan N (2020) Transplantation for primary hyperoxaluria type 1: designing new strategies in the era of promising therapeutic perspectives. Kidney Int Rep 5:2136–2145. https://doi.org/10.1016/j.ekir.2020.09.022CrossRefPubMedPubMedCentral

14.

Metry EL, Garrelfs SF, Peters-Sengers H, Hulton SA, Acquaviva C, Bacchetta J, Beck BB, Collard L, Deschênes G, Franssen C, Kemper MJ, Lipkin GW, Mandrile G, Mohebbi N, Moochhala SH, Oosterveld MJS, Prikhodina L, Hoppe B, Cochat P, Groothoff JW, OxalEurope Consortium (2021) Long-term transplantation outcomes in patients with primary hyperoxaluria type 1 included in the European Hyperoxaluria Consortium (OxalEurope) registry. Kidney Int Rep 7:210–220. https://doi.org/10.1016/j.ekir.2021.11.006CrossRefPubMedPubMedCentral

15.

Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O’Riordan WD, Cochat P, Deschênes G, Shasha-Lavsky H, Saland JM, van’t Hoff WG, Fuster DG, Magen D, Moochhala SH, Schalk G, Simkova E, Groothoff JW, Sas DJ, Meliambro KA, Lu J, Sweetser MT, Garg PP, Vaishnaw AK, Gansner JM, McGregor TL, Lieske JC; ILLUMINATE-A Collaborators (2021) Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med 384:1216–1226. https://doi.org/10.1056/NEJMoa2021712CrossRefPubMed

16.

Hoppe B, Koch A, Cochat P, Garrelfs SF, Baum MA, Groothoff JW, Lipkin G, Coenen M, Schalk G, Amrite A, McDougall D, Barrios K, Langman CB (2022) Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria. Kidney Int 101:626–634. https://doi.org/10.1016/j.kint.2021.08.015CrossRefPubMed

17.

Scott LJ, Keam SJ (2021) Lumasiran: first approval. Drugs 81:277–282. https://doi.org/10.1007/s40265-020-01463-0CrossRefPubMed

18.

Shee K, Stoller ML (2022) Perspectives in primary hyperoxaluria - historical, current and future clinical interventions. Nat Rev Urol 19:137–146. https://doi.org/10.1038/s41585-021-00543-4CrossRefPubMed

19.

Rhuma NR, Fituri OA, Sabei LT (2018) Mutational analysis of AGXT gene in Libyan children with primary hyperoxaluria type 1 at Tripoli Children Hospital. Saudi J Kidney Dis Transpl 29:30–38. https://doi.org/10.4103/1319-2442.225202CrossRefPubMed

20.

Nagara M, Tiar A, Ben Halim N, Ben Rhouma F, Messaoud O, Bouyacoub Y, Kefi R, Hassayoun S, Zouari N, Ben Ammar MS, Abdelhak S, Chemli J (2013) Mutation spectrum of primary hyperoxaluria type 1 in Tunisia: implication for diagnosis in North Africa. Gene 527:316–320. https://doi.org/10.1016/j.gene.2013.06.023CrossRefPubMed

21.

Guillaume A, Chiodini B, Adams B, Dahan K, Deschênes G, Ismaili K (2021) The struggling odyssey of infantile primary hyperoxaluria. Front Pediatr 9:615183. https://doi.org/10.3389/fped.2021.615183CrossRefPubMedPubMedCentral

22.

Soliman NA, Elmonem MA, Abdelrahman SM, Nabhan MM, Fahmy YA, Cogal A, Harris PC, Milliner DS (2022) Clinical and molecular characterization of primary hyperoxaluria in Egypt. Sci Rep 12:15886. https://doi.org/10.1038/s41598-022-17980-9CrossRefPubMedPubMedCentral

23.

Al Riyami MS, Al Ghaithi B, Al Hashmi N, Al Kalbani N (2015) Primary hyperoxaluria type 1 in 18 children: genotyping and outcome. Int J Nephrol 2015:634175. https://doi.org/10.1155/2015/634175CrossRefPubMedPubMedCentral

24.

Fadel FI, Kotb MA, Abdel Mawla MA, Hasanin RM, Salem AM, Fathallah MG, Amr KS, Ahmed HA, Salah DM (2022) Primary hyperoxaluria type 1 in children: clinical classification, renal replacement therapy, and outcome in a single centre experience. Ther Apher Dial 26:162–170. https://doi.org/10.1111/1744-9987.13666CrossRefPubMed

25.

Hopp K, Cogal AG, Bergstralh EJ, Seide BM, Olson JB, Meek AM, Lieske JC, Milliner DS, Harris PC, Rare Kidney Stone Consortium (2015) Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J Am Soc Nephrol 26:2559–2570. https://doi.org/10.1681/ASN.2014070698CrossRefPubMedPubMedCentral

26.

Harambat J, van Stralen KJ, Espinosa L, Groothoff JW, Hulton SA, Cerkauskiene R, Schaefer F, Verrina E, Jager KJ, Cochat P, European Society for Pediatric Nephrology/European Renal Association-European Dialysis and Transplant Association (ESPN/ERA-EDTA) Registry (2012) Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy. Clin J Am Soc Nephrol 7:458–465. https://doi.org/10.2215/CJN.07430711CrossRefPubMedPubMedCentral

27.

Bergstralh EJ, Monico CG, Lieske JC, Herges RM, Langman CB, Hoppe B, Milliner DS; IPHR Investigators (2010) Transplantation outcomes in primary hyperoxaluria. Am J Transplant 10:2493–2501. https://doi.org/10.1111/j.1600-6143.2010.03271.xCrossRefPubMedPubMedCentral

28.

Bunchman TE, Swartz RD (1994) Oxalate removal in type I hyperoxaluria or acquired oxalosis using HD and equilibration PD. Perit Dial Int 14:81–84CrossRefPubMed

29.

Illies F, Bonzel KE, Wingen AM, Latta K, Hoyer PF (2006) Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1. Kidney Int 70:1642–1648. https://doi.org/10.1038/sj.ki.5001806CrossRefPubMed

30.

Hoppe B, Graf D, Offner G, Latta K, Byrd DJ, Michalk D, Brodehl J (1996) Oxalate elimination via hemodialysis or peritoneal dialysis in children with chronic renal failure. Pediatr Nephrol 10:488–492. https://doi.org/10.1007/s004670050145CrossRefPubMed

Titel: Primary hyperoxaluria type 1 in children: clinical and laboratory manifestations and outcome
verfasst von: Hala Wannous
Publikationsdatum: 14.03.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Pediatric Nephrology / Ausgabe 8/2023
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-023-05917-x

Neu im Fachgebiet Pädiatrie

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

16.05.2024 Arterielle Hypertonie in der Pädiatrie Nachrichten

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2023

Proteinuria and hematuria in a 9-year-old girl after allogeneic hematopoietic stem cell transplantation: Questions

Membranous nephropathy in a female patient with X-linked thrombocytopenia

Variants in complement genes are uncommon in patients with anti-factor H autoantibody-associated atypical hemolytic uremic syndrome

Exstrophy-epispadias complex: are the kidneys and kidney function spared?